Enzoheal D Tablet is a combination pharmaceutical formulation containing Trypsin 48 mg, Bromelain 90 mg, Rutoside 100 mg, and Diclofenac 50 mg, designed to provide effective anti-inflammatory, analgesic, and fibrinolytic actions. Trypsin and Bromelain are proteolytic enzymes that facilitate the breakdown of proteins, promoting the reduction of edema and inflammation by enhancing the absorption of inflammatory exudates. Rutoside, a bioflavonoid, contributes to vascular protection by strengthening capillary walls and reducing capillary permeability, thereby minimizing bruising and hemorrhagic tendencies. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), exerts potent analgesic and anti-inflammatory effects by inhibiting cyclooxygenase enzymes, leading to decreased prostaglandin synthesis. The synergistic action of these components makes Enzoheal D effective in managing conditions characterized by inflammation, pain, and swelling, such as musculoskeletal injuries, postoperative edema, and soft tissue inflammatory disorders. It is indicated for use in acute trauma, sprains, strains, and post-surgical recovery to accelerate healing and improve patient comfort. Enzoheal D should be administered under medical supervision, with caution advised in patients with hypersensitivity to NSAIDs, bleeding disorders, or gastrointestinal ulcers. Adherence to prescribed dosage and duration is essential to optimize therapeutic outcomes and minimize potential adverse effects.